In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model

Current Drug Discovery Technologies

Volumn 4, Issue 2, 2007, Pages 126-132

  Ramaprasad, Subbaraya ^a   Ripp, Elzbieta ^c   Missert, Joseph ^b   Pandey, Ravindra K ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NONE

Author keywords

19F MR; Fluorine labeled photosensitizers; Pharmacokinetics; Photodynamic therapy (PDT); Photofrin; RIF tumor

Indexed keywords

FLUORINE; PHOTOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; FIBROSARCOMA; FOOT; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR MODEL; ANIMAL; DISEASE MODEL; EXPERIMENTAL NEOPLASM; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSARCOMA; FLUORINE; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASMS, EXPERIMENTAL; PHOTOSENSITIZING AGENTS;

EID: 34548457744     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016307781483423     Document Type: Article

References (47)

1. Dougherty T.J., Kaufman J.H., Goldfarb A., Weishaupt K.R., Boyle D., Mittleman A.: Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 38, 2628, (1978).
2. Dougherty T.J: Therapy and detection of malignant tumors. Photochem. Photobiol. 45, 879, (1987).
3. Henderson B.W., Dougherty T.J.: How does photodynamic therapy work? Photochem. Photobiol. 55, 145, (1992).
4. Weishaupt K.R., Gomer C.J., Dougherty T.J.: Identification of singlet oxygen as the cytotoxic agent in photodynamic inactivation of a murine tumor. Cancer Res. 36, 2326, (1976).
5. Henderson B.W., Waldow S.M., Mang T.S., Potter W.R., Malone P.B., Dougherty T.J.: Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 45, 572, (1985).
6. Henderson B.W., Fingar V.H.: Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor. Cancer Res. 47, 3110, (1987).
7. Pandey R.K., Majchrzycki D.F., Smith K.M., Dougherty T.J.: Chemistry of Photofrin II and some new photosensitizers. Proc. SPIE. 1065, 164, (1989).
8. Evensen J.F., Sommer S., Rimington C, Moan J.: Photodynamic therapy of C3H mouse mammary carcinoma with hematoporphyrin di-ethers as sensitizers. Br. J. Cancer. 55,483, (1987).
9. Pandey R.K., Bellnier D.A., Smith K.M., Dougherty T.J.: Chlorin and porphyrin derivatives as potential photosensitizers in photodynamic therapy. Photochem. Photobiol. 53, 65, (1991).
10. Bellnier D.A., Henderson B.W., Pandey R.K., Potter W.R., Dougherty T.J.: Murine Pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-(1-hexoloxy ethyl)-2-devinyl pyropheophorbide-a. J. Photochem. Photobiol. B: Biol, 20, 55, (1993).
11. Pandey R.K., Sumlin A.A., Constantine S., Aoudala M., Potter WR., Bellnier D.A., Henderson B.W., Rodger M.A., et al.: Alkyl ether analogs of chlorophyll-a derivatives: part1 syntheses and photophysical properties and Photodynamic efficacy: Photochem. PhotoBiol. 64, 194, (1996).
12. Ando A., Shinada T., Kinishita S., Arinura N., Koyama M., Nagai T., Miki T., Kumadaki I., et al.: Synthesis of fluorine analogs of protoporphyrin potentially useful of diagnosis of therapy of tumors, Chem. Pharm. Bull 38, 2175, (1990).
13. 19F NMR spectroscopy. Eleventh SMRM Abstracts 2118, (1992).
14. 19F NMR imaging of glucose metabolism. Magn. Reson. Med. 6, 307, (1988).
15. Devoisselle J.M., Vion-Dury J., Confort-Gouny S., Coustaut D., Cozzone P.J.: Liposomes containing fluorinated steroids: An analysis based on photon correlation and fluorine-19 nuclear magnetic resonance spectroscopy. J. Pharm. Sci. 81, 248, (1992).
16. Maxwell R.J.: New techniques in the pharmacokinetic analysis of cancer drugs III Nuclear magnetic resonance, Cancer Surveys, Pharmacokinetics and cancer. Chemotherapy 17, 415, (1993).
17. Workman P., Maxwell R.L., Griffiths J.R.: Non-invasive MRS in new anticancer drug development. NMR Biomed. 5, 270, (1992).
18. Gewiese B.K.O., Noske W., Schilling A.M., Stiller D.A., Wolf K.J., Foerster W.H.: Human eye: Visualization of perfluorodecalin with F-19 MR imaging. Radiology 185, 131, (1992).
19. 19F NMR imaging of the cardiovascular system. J. Comput. Assist. Tomogr. 9, 1012, (1985).
20. 19F NMR imaging. J. Comput. Assist. Tomogr. 9, 8, (1985).
21. Jameson C.J.: Fluorine. in J. Mason (ed.). Multinuclear NMR. Chapter 16, 437, (1987).
22. 19F NMR spectroscopy of perfluorocarbon. Mag, Reson. Med. 29, 296 (1993).
23. Nakada T., Kwee I.L.: Noninvasive analysis of aldose reductase activities in rat testis. 3- FDG NMR spectroscopy and imaging. Magn. Reson. Med. 29, 543, (1993).
24. 19F NMR technique. Magn. Reson. Med. 9, 219, (1989).
25. 19F NMR imaging of cerebral blood flow. Magn. Reson. Med. 20, 151, (1990).
26. Partain C.L., Price R.R., Patton J.A., Kulkarni M.V., James Jr. A.E. eds.: S.R. Thomas: The biomedical applications of fluorine-19 NMR. Magnetic Resonance Imaging. 2, 1536, (1998).
27. Ceckler T.J., Gibson S.L., Hilf R., Bryant R.G.: In situ assessment of tumor vascularity using fluorine NMR imaging. Magn. Reson. Med. 13, 416, (1990).
28. 19F labeled photosensitizer in murine tumors. Proc. Soc. Magn. Reson. Med. 3, 1348, (1994).
29. 19F MR quantitation of fluorine labeled photosensitizers in tumors and normal tissue. Proc. Intl. Soc. Magn. Reson. Med. 11, (2004).
30. 19F magnetic resonance spectroscopy in vivo. Int. J. Radiat. Oncol. Biol. Phys. 16, 925, (1989).
31. Bourne D.W.A., Triggs E.J., Eadie M.J.: Pharmacokinetics for the Non-mathematical. MTP Press limited. (1986).
32. 19F NMR. Br. J. Cancer 50, 113, (1984).
33. 19F NMR spectroscopic pharmacokinetics in tumor bearing humans and rabbits. Proc. Natl. Acad. Sci. 87, 492, (1990).
34. Wolf W., Albright M.J., Silver MS., Reichardt U., Sauer R.: Fluorine-19 NMR spectroscopic studies of the metabolism of 5- fluorouracil in the liver of patients undergoing chemotherapy. Magn. Reson. Imaging. 5, 165, (1987).
35. Presant C.A., Wolf W., Waluch V., Wiseman C., Kennedy P., Blaney D., Brechner R.R.: Association of intratumoral pharmacokinetics of Fluorouracil with clinical Response. Lancet 343, 1184, (1994).
36. Pandey S.K., Gryshuk A.L., Graham A., Ohkubo K., Fukuzumi S., Dobhal M.P., Zheng G., Ou Z., et al.: Synthesis and in vitro photosensitizing efficacy of fluorinated porphyrin based photosensitizers for in vivo MR studies. Tetrahedron 59, 10059, (2003).
37. Gryshuk AL., Chen Y., Potter W., Ohulcharky T., Oseroff A., Pandey RK.: In vivo stability and photodynamic efficacy of fluorinated bacteriopur-purinimides derived from bacteriochlorophyl-a. J. Med. Chem. 49, 1874, (2006).
38. Li G., Graham A., Potter W., Grossman GD., Oseroff A., Dougherty TJ., Pandey RK.: A simple and efficient approach for the synthesis of fluorinated and nonfluorinated octaethylporphyrin-based benzochlorins with variable lipophilicity, their in vivo tumor uptake and preliminary in vitro photosensitizing efficacy. J. Org. Chem. 66, 1316, (2001).
39. Songca SP.: In vivo activity and tissue distribution of new fluorinated meso-tetrahydroxy phenyl porphyrin photosensitizers. J. Pharm. Pharmacol. 53, 1469, (2001).
40. Ko Y.J., Yun K.J., Kang M.S., Park J., Lee K.T., Park S.B., Shin JH.: Synthesis and in vitro photodynamic activities of water soluble fluorinated tetrapyridyl porphyrins as tumor photosensitizers. Biorganic Med. Chem. Lett. 17, 2789, (2007).
41. Grancho J.C.P., Pereira M.M., Miguel da G., Rocha Gonzales A.M., Burrows H.D.: Synthesis, spectra and photophysics of some free base tetrafluoroalkyl and tetrafluoroaryl porphyrins with potential applications in imaging. Photochem. Photobiol. 75, 249, (2002).
42. Twentyman P.R., Brown J.M., Gray J.W., Franko A.J., Scoles M.A., Kallman R.F.: A New mouse tumor model system (RIF-1) for comparison of end point studies, J Nat Cancer Inst. 64, 595, (1980).
43. Denekamp J.: The choice of experimental models in cancer research: The key to ultimate success or failure? NMR Biomed. 5, 234, (1992).
44. Soher B.J., van Zijl P.C.M., Duyn J.H., Barker P.B.: Quantitative proton imaging of human brain. Magn. Reson. Med. 35, 356, (1996).
45. PK Solutions (version 2.0) Summit Research Services, Colorado, (2001).
46. Bellnier D.A., HO Y.K., Pandey R.K., Missert J.R., Dougherty T.J.: Distribution and elimination of Photofrin II in mice. Photochem Photobiol. 50, 221, (1989).
47. Houle J.M., Strong A.: Clinical pharmacokinetics of verteporfin. J. Clin. Pharmacol. 42, 547, (2002).